Close Menu

NEW YORK – Biocept reported after the close of the market on Thursday that its third quarter revenues more than quadrupled year over year driven by its current offering of molecular COVID-19 testing services.

For the three months ended Sept. 30, the San Diego-based liquid biopsy company posted $6.6 million in revenues compared to $1.5 million in Q3 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.